En Carta Diagnostics
PrivateLast Round
Seed
Jul 10, 2026
Est. Valuation
$33M
Total Funding Raised
$7.34M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
En Carta Diagnostics is a biotechnology company that develops rapid point-of-care molecular diagnostic kits with an initial focus on the early diagnosis of Lyme disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
En Carta Diagnostics Comparables
Compare En Carta Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anavasi Diagnostics | 79% | |
| ExGen Dx | 77% | |
| Anywhere Dx | 73% |
En Carta Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jul 10, 2026 | ||||
| Pre Seed | May 22, 2024 |
En Carta Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Paris Biotech Santé | Pre Seed |
| 50 Partners | Pre Seed, Seed |
| Blue Forest Ventures | Seed |
| CentraleSupélec Venture | Seed, Pre Seed |
| Ring Capital | Seed |
| Bpifrance | Seed |
| PC'up Incubator | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 33% MoM, reaching 4K.
- Jul 25, 2026
Monthly visitors increased 59% MoM, from 1.9K to 3K.
Recent news
Latest coverage and updates
- is_developingJul 13, 2026
Encarta is developing molecular diagnostic platforms designed for home use: as easy to use as a rapid test on Jul 13th '26.
- receives_financingJul 13, 2026
En Carta received financing of $5.71M in financing on Jul 10th '26.
En Carta Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about En Carta Diagnostics's valuation, stock price, and market status.
Is En Carta Diagnostics a public or private company?
En Carta Diagnostics is a private company.
What is the current stock price of En Carta Diagnostics?
En Carta Diagnostics is a private company with no public stock price. No recent secondary market data is available.
How much is En Carta Diagnostics worth (valuation)?
Valuation information for En Carta Diagnostics is not publicly available.
Can I buy En Carta Diagnostics stock?
En Carta Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was En Carta Diagnostics's last funding round?
En Carta Diagnostics's most recent funding round was Pre Seed on May 22, 2024.
Who are the main investors in En Carta Diagnostics?
Key investors in En Carta Diagnostics include CentraleSupélec Venture.
Will En Carta Diagnostics IPO soon?
No public IPO plans have been announced for En Carta Diagnostics.
How can I track En Carta Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor En Carta Diagnostics's secondary market activity and sign up for updates.